PT  - JOURNAL ARTICLE
AU  - Weiskopf, Daniela
AU  - Schmitz, Katharina S.
AU  - Raadsen, Matthijs P.
AU  - Grifoni, Alba
AU  - Okba, Nisreen M.A.
AU  - Endeman, Henrik
AU  - van den Akker, Johannes P.C.
AU  - Molenkamp, Richard
AU  - Koopmans, Marion P.G.
AU  - van Gorp, Eric C.M.
AU  - Haagmans, Bart L.
AU  - de Swart, Rik L.
AU  - Sette, Alessandro
AU  - de Vries, Rory D.
TI  - Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome
AID  - 10.1101/2020.04.11.20062349
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.11.20062349
4099  - http://medrxiv.org/content/early/2020/05/29/2020.04.11.20062349.short
4100  - http://medrxiv.org/content/early/2020/05/29/2020.04.11.20062349.full
AB  - SARS-CoV-2 has been identified as the causative agent of a global outbreak of respiratory tract disease (COVID-19). In some patients the infection results in moderate to severe acute respiratory distress syndrome (ARDS), requiring invasive mechanical ventilation. High serum levels of IL-6 and an immune hyperresponsiveness referred to as a ‘cytokine storm’ have been associated with poor clinical outcome. Despite the large numbers of cases and deaths, information on the phenotype of SARS-CoV-2-specific T-cells is scarce. Here, we detected SARS-CoV-2-specific CD4+ and CD8+ T cells in 100% and 80% of COVID-19 patients, respectively. We also detected low levels of SARS-CoV-2-reactive T-cells in 20% of the healthy controls, not previously exposed to SARS-CoV-2 and indicative of cross-reactivity due to infection with ‘common cold’ coronaviruses. Strongest T-cell responses were directed to the surface glycoprotein (spike, S), and SARS-CoV-2-specific T-cells predominantly produced effector and Th1 cytokines, although Th2 and Th17 cytokines were also detected. Collectively, these data stimulate further studies into the role of T-cells in COVID-19, support vaccine design and facilitate the evaluation of vaccine candidate immunogenicity.Summary COVID-19 is associated with lymphopenia and ‘cytokine storm’, but there is a scarcity of information on specific cellular immune responses to SARS-CoV-2. Here, we characterized SARS-CoV-2-specific CD4+ and CD8+ T-cells in patients hospitalized with acute respiratory distress syndrome (ARDS).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study was not a clinical trial where intervention strategies were tested, rather clinical material from COVID-19 patients were used. Ethical statements are provided in the manuscript.Funding StatementNo dedicated funding was used for acquiring the data presented in this manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in this manuscript (and its supplementary information files).